2025 ICD-10-CM code C94.32
(Active) Effective Date: N/A Neoplasms - Mast cell leukemia, in relapse 2 Feed
Mast cell leukemia, a rare and aggressive subtype of acute myeloid leukemia (AML), in relapse. This signifies the recurrence of signs and symptoms after a period of remission.
Medical necessity for treatment of relapsed mast cell leukemia is established by the confirmation of the relapse through clinical and laboratory findings.Treatment is directed towards managing the disease and alleviating symptoms.
The physician plays a crucial role in diagnosing and managing mast cell leukemia. This involves evaluating the patient's history, conducting physical examinations, ordering laboratory tests (CBC, peripheral smear, blood chemistries, coagulation studies), performing bone marrow biopsies, and utilizing imaging studies (CT, MRI, PET scans, ultrasound). Treatment decisions are based on the disease stage and patient age and may include chemotherapy (alone or in combination with targeted therapy or interferon), stem cell transplant, radiation therapy, or surgery.
- 2
- Malignant neoplasms (C00-C96)Malignant neoplasms, stated or presumed to be primary (of specified sites), and certain specified histologies, except neuroendocrine, and of lymphoid, hematopoietic and related tissue (C00-C75)Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
In simple words: Mast cell leukemia is a rare type of blood cancer that becomes more aggressive when it comes back after treatment.It's like having a remission from cancer and having it return.
Mast cell leukemia is a rare subtype of acute myeloid leukemia (AML) characterized by the abnormal proliferation of mast cells in the peripheral blood.This code (C94.32) is used when the patient has experienced a relapse, meaning the disease has returned after a period of remission (disappearance of signs and symptoms).
Example 1: A patient with mast cell leukemia achieves remission after initial chemotherapy but presents months later with recurrent symptoms (fatigue, bone pain, splenomegaly).Code C94.32 is used to indicate the relapse., A patient diagnosed with mast cell leukemia undergoes a stem cell transplant after achieving remission. A year later, tests reveal the disease has returned. C94.32 is used to document the relapse., A patient with mast cell leukemia in remission experiences a recurrence of symptoms and tests confirm the disease's return.Despite receiving targeted chemotherapy during the initial treatment, the relapse is documented with C94.32.
Documentation should include details of the initial diagnosis, treatment received, period of remission, evidence of relapse (clinical findings, laboratory results, imaging studies), and the treatment plan for the relapsed disease.
- Specialties:Hematology, Oncology
- Place of Service:Inpatient Hospital, Office